Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA 01.06.2025

Full Press ReleaseSEC FilingsOur NTLA Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
  • 01.13.2025 - J.P. Morgan Healthcare Conference
  • 01.09.2025 - Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

Recent Filings

  • 01.10.2025 - EX-99.1 EX-99.1
  • 01.10.2025 - 8-K Current report
  • 01.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors

CAMBRIDGE, Mass,Jan. 06, 2025(GLOBE NEWSWIRE) --Intellia Therapeutics, Inc.(NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that onJanuary 1, 2025, it awarded inducement grants to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for 23,155 shares of Intellia’s common stock, with one-third of such RSUs vesting onJanuary 1, 2026, 2027, and 2028.

All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors inJune 2024. The awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

AboutIntellia Therapeutics

Intellia Therapeutics, Inc.(NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’sin vivoprograms use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’sex vivoprograms use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more atintelliatx.comand follow us@intelliatx.

Intellia Contacts:

Investors:

Brittany ChavesSenior Manager, Investor RelationsBrittany.Chaves@intelliatx.com

Primary Logo

Source: Intellia Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com